RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Tranzyme Pharma today announced that it has initiated dosing in a Phase 2 study of TZP-102, its potent and selective second generation oral ghrelin agonist, in diabetic patients with gastroparesis. Gastroparesis is an inability of the stomach to empty food efficiently, and comprises a prevalent and serious complication of diabetes mellitus. The characteristics of the compound allow for chronic administration in an out-patient setting.
